Bli medlem
Bli medlem

Du är här

2020-08-14

PEPTONIC Medical AB: Peptonic Medical receives new order for VagiVital ® from Shijiazhuang Yuanjia Biotechnology Co. Ltd.

The Products are to be used for a large scale study to collect user experience data to support the registration process in China and for building brand awareness among gynaecologists and gynaecology clinics across the country.  The Products will be sold via Yuanjia Bio's extensive distribution network and on-line via the local VagiVital®webshop (www.vagivital.cn).

  • This order is an indication of the high level activity by Yuanjia Bio in support of the marketing authorization application and subsequent full scale launch of VagiVital® , says Dr Johan Inborr, CEO of Peptonic Medical.

The process of obtaining marketing approval for VagiVital® in China is progressing according to plan, and is expected to be completed during the first quarter of 2021.

Through its market research in China, Yuanjia Bio has identified four primary target patient groups for VagiVital®, including e.g. menopausal and post-partum women, with a total number of approximately 415 million women. China's so called `gyneacological inflammatory market' was estimated to reach 26.9 billion yuan (approx. 3.5 billion Euro) in sales in 2018. Between 2013 and 2017, this market grew at a rate of 7.6 percent annually.

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.